A concise and selective synthesis of novel 5-aryloxyimidazole NNRTIs.
[reaction: see text] A concise and efficient route to the construction of a 5-aryloxyimidazole has been developed. The key step was the selective O-arylation of a 2,4-dimethoxybenzyl-protected imidazolone. The final compound is a potent inhibitor of HIV reverse transcriptase.
Jones
Lyn H
LH
Sandwich Laboratories, Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ, UK. lyn.jones@pfizer.com
Dupont
Thomas
T
Mowbray
Charles E
CE
Newman
Sandra D
SD
D019380:Anti-HIV Agents / Q000138:chemical synthesis*; D007093:Imidazoles / Q000138:chemical synthesis* / Q000737:chemistry; D015394:Molecular Structure; D018894:Reverse Transcriptase Inhibitors / Q000138:chemical synthesis*; D013457:Sulfur Compounds / Q000138:chemical synthesis* / Q000737:chemistry
D019380:Anti-HIV Agents; D007093:Imidazoles; D018894:Reverse Transcriptase Inhibitors; D013457:Sulfur Compounds; C433874:capravirine